A Qualitative Analysis of Cancer Survivors' Experience in a Time-Restricted Eating vs Control Clinical Trial to Address Cancer-Related Fatigue.

Semin Oncol NursJun 13, 2026 (epub)
Clinical ResearchOncology (Medical)

Jackson R Kerner, Carin L Clingan, Oxana Palesh et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial explored the experiences of 24 adult cancer survivors participating in a study comparing individualized nutrition counseling with and without time-restricted eating to address cancer-related fatigue. Participants reported that the study helped them achieve lifestyle goals, with many in the time-restricted eating group appreciating the routine it provided. Overall, the study was deemed beneficial for enhancing dietary control.

Key findings

  • The majority of participants recommended the study to others for its helpfulness in achieving lifestyle goals.
  • Participants in the time-restricted eating group reported improved routine and a sense of control.
  • Some participants experienced challenges adapting to a 14-hour fasting schedule due to routine conflicts.

Why it matters

Understanding cancer survivors' experiences with dietary interventions can inform future supportive care strategies aimed at alleviating cancer-related fatigue and improving quality of life.

Source

PubMed · PMID 42285824

Published in Semin Oncol Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.